NCT05853575 2026-02-17Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Mirati Therapeutics Inc.Phase 2 Recruiting200 enrolled
NCT04975256 2024-12-16Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)Mirati Therapeutics Inc.Phase 1 Terminated7 enrolled
NCT05848843 2024-01-23A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C MutationsM.D. Anderson Cancer CenterPhase 1 Withdrawn